Table 3 Prevalence of abnormal lipid profiles among patients treated with NRTIs and NNRTIs based antiretroviral regimens
NRTIs based regimens | |||
|---|---|---|---|
Lipid profile | AZT based (n = 82) | TDF based (n = 75) | p-value |
Total cholesterol, mean ± SD | 205.2 (66.3) | 212.3 (77.8) | 0.540 |
≥ 200 mg/dL | 41 (50.0 %) | 39 (52.0 %) | 0.802 |
LDL-cholesterol, mean ± SD | 115.9 (63.2) | 119.5 (73.6) | 0.744 |
≥ 130 mg/dL | 27 (32.9 %) | 31 (41.3 %) | 0.276 |
HDL-cholesterol, mean ± SD | 70.1 (29.9) | 63.7 (25.6) | 0.153 |
< 40 mg/dL | 13 (15.9 %) | 9 (12.0 %) | 0.482 |
Triglycerides, mean ± SD | 102.4 (46.9) | 133.4 (67.1) | 0.009 |
≥ 150 mg/dL | 12 (14.6 %) | 20 (26.7 %) | 0.060 |
TC/HDL-cholesterol ratio, mean ± SD | 3.6 (2.7) | 3.9 (2.4) | 0.405 |
≥ 5 | 12 (14.6 %) | 12 (16.0 %) | 0.808 |
NNRTIs based regimens | |||
|  | NVP based (n = 101) | EFV based (n = 43) |  |
Total cholesterol, mean ± SD | 204.1 (65.5) | 218.7 (90.6) | 0.282 |
≥ 200 mg/dL | 49 (48.5 %) | 23 (53.5 %) | 0.583 |
LDL-cholesterol, mean ± SD | 114.6 (61.2) | 126.5 (87.7) | 0.353 |
≥ 130 mg/dL | 36 (35.6 %) | 17 (39.5 %) | 0.657 |
HDL-cholesterol, mean ± SD | 68.3 (29.5) | 63.8 (22.5) | 0.370 |
< 40 mg/dL | 17 (16.8 %) | 3 (7.0 %) | 0.119 |
Triglycerides, mean ± SD | 105.4 (29.5) | 136.0 (75.4) | 0.004 |
≥ 150 mg/dL | 15 (14.9 %) | 12 (27.9 %) | 0.068 |
TC/HDL-cholesterol ratio, mean ± SD | 3.6 (2.7) | 3.9 (2.3) | 0.635 |
≥ 5 | 16 (15.8 %) | 7 (16.3 %) | 0.940 |